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Philadelphia-chromosome-positive (Ph) acute lymphoblastic
leukemia (ALL) accounts for 3–5% of childhood ALL, and allo-
geneic hematopoietic stem cell transplantation (HSCT) is consid-
ered to be the best way to cure the relatively rare and aggressive
subtype of ALL. Cytarabine is an effective agent in both lymphoid
and myeloid leukemia, and high-dose cytarabine (HDC) has been
used to treat patients with ALL who had relapsed or had been
refractory to the standard induction chemotherapy. From this
point of view, we postulated that the addition of HDC to the
standard conditioning regimen might decrease the relapse rate
through more effective eradication of residual leukemia before
transplant. So, we investigated the feasibility of HDC-containing
conditioning for the treatment of children with Ph ALL. Be-
tween February 2002 and May 2005, 10 consecutive patients with
Ph ALL, including one who had presented with CML in lym-
phoid blastic phase, aged 3.5–12.8 years (median age 9.4 years)
received allogeneic HSCT at our two cooperative institutions. The
median time from diagnosis to transplant was 6 months (range,
3–10 mo). Two patients (20%) were not in CR1 at transplant. The
sources of stem cells were as follows: unrelated bone marrow (n 
5), unrelated cord blood (n  4), matched sibling bone marrow
(n  1). The conditioning regimen included HDC (3 g/m2/dose
every 12 h  4 doses, total 12 g/m2), cyclophosphamide (60
mg/kg/day  2 days, total 120 mg/kg), and total body irradiation
(TBI). TBI was delivered in 2 different manners according to the
each institutional guideline (1000 cGy/3 Fr/3 day, n  5; 1320
cGy/11 Fr/4 day, n  5). Cyclosporine with or without other
agents was used for GVHD prophylaxis. The neutrophil recovery
was attained in all recipients at a median of 20.5 days (range, 11–44
days) and the platelet engraftment also occurred in all patients at a
median of 26.5 days (range, 13–148 days). Grade 2-4 and grade 3-4
acute GVHD were developed in 4 (40%) and 2 (20%) patients,
respectively. Three patients (30%) developed chronic GVHD (2
limited, 1 extensive). All but one patient are alive disease-free with
a median follow-up of 21 months (range, 4–39 months). There was
no relapse and the only event was a chronic pulmonary GVHD
with bronchiolitis obliterans leading to death in 1 patient. The
3-year estimated event-free survival was 83.3%. In conclusion, our
results suggest that adding HDC to the standard Cy/TBI condi-
tioning is feasible in allogeneic HSCT for pediatric patients with
Ph ALL.
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From 1/00 to 4/05, 93 patients (pts) with AML underwent allo
HSCT at the VU/VA SCT program. Variables including donor
type, stem cell source, regimen intensity, and degree of HLA
matching were analyzed for their effect on OS and TTP. Median
age at transplant was 47 (19–66). 85 pts (91%) had poor risk
disease, deﬁned as prior MDS or MPD (n  17), poor-risk cyto-
genetics (n  6), refractory disease (n  4), relapsed disease (n 
15), history of chemotherapy and/or radiotherapy for a prior ma-
lignancy (n 4), CR2 (n 35), or requiring	1 cycle of induction
to achieve CR1 (n 4). Regimens were either full-dose (BuCy and
CyTBI) or reduced-dose (FluBu, FluBuTBI, or FluTBI). Of the 93
pts, 62 (67%) had matched related donors (MRD) and 31 (33%)
had unrelated donors (URD). Both groups (MRD vs URD) were
similar in disease risk (87% vs 100% high risk), degree of HLA
matching (98% vs 77% fully matched), and regimen intensity (79%
vs 77% full-dose) but differed signiﬁcantly in stem cell source with
MRD 95% PBSC and URD 71% BM, P  .001. Day 100 mor-
tality was 11% for MRD versus 29% for URD, and all pts surviving
to day 30 engrafted (ANC	500). Median OS was 10.8 months and
was not signiﬁcantly affected by donor type, regimen intensity, or
pt age. OS was signiﬁcantly higher in pts with fully-matched
donors (median 12.9 months vs 2.4 mos, P  .027) and in pts
without high-risk disease (median not reached vs 8.0 months, P 
.040). There was also a trend towards improved survival of pts
receiving PBSC versus BM (median 13.4 mos vs 6.7, P  .062).
Interestingly, pts receiving full-dose regimens were more likely to
die of relapse than transplant-related mortality (TRM) (30 relapse
vs 16 TRM), while pts receiving reduced-dose regimens had more
TRM than relapse deaths (3 relapse vs 9 TRM, P  .02), which
may be accounted for by the higher median age of the reduced-
dose group (56 vs 43). Of the 93 pts, 35 (38%) are alive with a
median follow-up of 18.0 mos (5.5–61.8), 35 (38%) have died of
relapse, and 23 (25%) TRM. TTP was 31.4 months with censor-
ship of pts with TRM. OS at 36 months was 33%. Using a
Cox-proportional multivariate model, only disease risk approached
signiﬁcance with a hazard ratio of 3.6 (P  .079). These results
highlight the need for better anti-leukemic regimens and indicate
that allo HSCT is most beneﬁcial to pts who have chemotherapy-
responsive disease and few risk factors for TRM, but can still
salvage approximately 1/3 of patients with poor risk disease.
251
THE EARLY REFERRAL FOR REDUCED-INTENSITY STEM CELL TRANS-
PLANTATION IN PATIENTS WITH Ph1 () CHRONIC MYELOGENOUS
LEUKEMIA IN CHRONIC PHASE IN THE IMATINIB ERA: RESULTS OF
THE LATIN AMERICAN COOPERATIVE ONCOHEMATOLOGY GROUP (LA-
COHG) PROSPECTIVE, MULTICENTER STUDY
Ruiz-Arguelles, G.J.1,2, Gomez-Almaguer, D.3, Morales-Toquero, A.1,
Gutierrez-Aguirre, C.H.3, Vela-Ojeda, J.4, Garcia-Ruiz-Esparza,
M.A.4, Manzano, C.1, Karduss, A.5, Sumoza, A.6, de-Souza, C.7,
Miranda, E.7, Giralt, S.8 1. Centro de Hematologia y Medicina Interna
de Puebla, Puebla, Mexico; 2. Laboratorios Clinicos de Puebla, Puebla,
Mexico; 3. Hospital Universitario de Monterrey, Monterrey, Nuevo
Leon, Mexico; 4. Centro Medico La Raza, IMSS, Mexico City, Mexico;
5. Instituto de Cancerologia. Clinica las Americas, Medellin, Colombia;
6. Universidad de Carabobo, Valencia, Venezuela; 7. Universidad de
Campinas, Sao Paulo, Brazil; 8. M. D. Anderson Cancer Center,
Houston, TX.
Using a reduced intensity stem cell transplantation (RIST)
schedule, 24 patients with Ph1 () chronic myelogenous leukemia
(CML) in ﬁrst chronic phase were prospectively allografted in 4
Latin American countries: Mexico, Brasil, Colombia, and Venezu-
ela, using HLA-identical siblings as donors. Median age of the
patients was 41 years (range 10–71); there were 8 females. Patients
received a median of 4.4  106/Kg CD34 cells. Median time to
achieve above 0.5  109/L granulocytes was 12 days, range 0–41,
whereas median time to achieve above 20  109/L platelets was
also 12 days, range 0–45. Twenty two patients are alive 81 to 830
(median 497) days after the RIST. The 830-day probability of
survival is 92%, whereas median survival has not been reached,
being above 830 days. Eleven patients (46%) developed acute
graft-versus-host disease (GVHD), whereas 7 of 23 (30%) devel-
oped chronic GVHD. Two patients died 43 and 210 days after the
RIST, one as a result of sepsis and the other one of chronic
GVHD. The 100-day mortality was 4.4 %, whereas the transplant-
related mortality was 8%. RIST for patients with CML in chronic
phase seems as an adequate therapeutic option.
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Hyper-CVAD (fractionated cyclophosphamide, vincristine,
doxorubicin, and dexamethasone) alternating with high-dose
methotrexate-cytarabine has proven to be an effective regimen in
the treatment of adult ALL. Addition of the anti-CD20 monoclo-
nal antibody rituximab to standard chemotherapy regimens has
shown signiﬁcant beneﬁt in the treatment of lymphoma and leu-
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kemia expressing CD20. There is minimal data describing addition
of rituximab to hyper-CVAD in the treatment of CD20 ALL.
We report 8 patients with CD20 ALL treated with rituximab and
hyperCVAD. Disease subtypes were precurser B-cell ALL (6),
CML in lymphoid blast phase (1), and Burkitt’s lymphoma (1). In
addition to the patient with CML, one additional patient was
Philadelphia chromosome-positive. These two patients received
imatinib mesylate 400 mg on days 1–14 of each treatment cycle.
Rituximab was administered at a dose of 375 mg/m2 on day 1 of
each cycle of chemotherapy. Six patients achieved a complete
remission (CR) by bone marrow analysis; 1 patient had normaliza-
tion of the hematologic picture and was assumed to have achieved
a CR, however, this was not conﬁrmed with a bone marrow
assessment due to patient-speciﬁc concerns; and 1 patient achieved
a partial response (PR) deﬁned as more than 50% reduction in
nodal/mediastinal disease with clearance of the bone marrow. Me-
dian progression-free and overall survival have not been reached.
All surviving patients are also disease-free with a range of 2 to
51 months from initiation of therapy. All patients tolerated the
addition of rituximab well and there were no deaths due to treat-
ment complications. Three patients have expired due to relapse of
disease (6, 9, and 12 month survival) and one patient expired
because of infection following allogeneic transplant. Rituximab
appears to be a reasonable addition to hyper-CVAD in the treat-
ment of CD20 adult ALL and should be considered as part of
pre-transplant cytoreductive therapy for high-risk patients. Larger
studies need to be done to further evaluate the response and
survival rates.
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